{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:08:26Z","timestamp":1788570506058,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical Medicine + X Research Project of the Affiliated Hospital of Qingdao University in 2024","award":["QDFY+X2024212"],"award-info":[{"award-number":["QDFY+X2024212"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04125-1","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T07:52:17Z","timestamp":1753343537000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of vedolizumab in elderly and younger patients with moderate-to-severe ulcerative colitis: a retrospective real-world study in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Xian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Bin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-0710","authenticated-orcid":false,"given":"Ai-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"4125_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00535-019-01580-y","volume":"54","author":"M Higashiyama","year":"2019","unstructured":"Higashiyama M, Sugita A, Koganei K, Wanatabe K, Yokoyama Y, Uchino M, Nagahori M, Naganuma M, Bamba S, Kato S, et al. Management of elderly ulcerative colitis in Japan. J Gastroenterol. 2019;54:571\u201386.","journal-title":"J Gastroenterol"},{"key":"4125_CR2","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/ueg2.12350","volume":"10","author":"S Aniwan","year":"2022","unstructured":"Aniwan S, Santiago P, Loftus EJ, Park SH. The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries. United Eur Gastroent. 2022;10:1063\u201376.","journal-title":"United Eur Gastroent"},{"key":"4125_CR3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/jgh.14872","volume":"35","author":"WY Mak","year":"2020","unstructured":"Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East Meets West. J Gastroen Hepatol. 2020;35:380\u20139.","journal-title":"J Gastroen Hepatol"},{"key":"4125_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.dld.2022.12.024","volume":"55","author":"P Sousa","year":"2023","unstructured":"Sousa P, Bertani L, Rodrigues C. Management of inflammatory bowel disease in the elderly: A review. Digest Liver Dis. 2023;55:1001\u20139.","journal-title":"Digest Liver Dis"},{"key":"4125_CR5","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/apt.14494","volume":"47","author":"M Manosa","year":"2018","unstructured":"Manosa M, Calafat M, de Francisco R, Garcia C, Casanova MJ, Huelin P, Calvo M, Tosca J, Fernandez-Salazar L, Arajol C, et al. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case-control study. Aliment Pharm Ther. 2018;47:605\u201314.","journal-title":"Aliment Pharm Ther"},{"key":"4125_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"T Wyant","year":"2016","unstructured":"Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody Vedolizumab. J Crohns Colitis. 2016;10:1437\u201344.","journal-title":"J Crohns Colitis"},{"key":"4125_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14740338.2017.1300251","volume":"16","author":"G Novak","year":"2017","unstructured":"Novak G, Hindryckx P, Khanna R, Jairath V, Feagan BG. The safety of Vedolizumab for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017;16:501\u20137.","journal-title":"Expert Opin Drug Saf"},{"key":"4125_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1093\/gastro\/goz041","volume":"8","author":"P Shashi","year":"2020","unstructured":"Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of Vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep. 2020;8:306\u201311.","journal-title":"Gastroenterol Rep"},{"key":"4125_CR9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1177\/2050640620951400","volume":"8","author":"NA Cohen","year":"2020","unstructured":"Cohen NA, Plevris N, Kopylov U, Grinman A, Ungar B, Yanai H, Leibovitzh H, Isakov NF, Hirsch A, Ritter E, et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United Eur Gastroent. 2020;8:1076\u201385.","journal-title":"United Eur Gastroent"},{"key":"4125_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/apt.16923","volume":"56","author":"D Pugliese","year":"2022","unstructured":"Pugliese D, Privitera G, Crispino F, Mezzina N, Castiglione F, Fiorino G, Laterza L, Viola A, Bertani L, Caprioli F, et al. Effectiveness and safety of Vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study. Aliment Pharm Ther. 2022;56:95\u2013109.","journal-title":"Aliment Pharm Ther"},{"key":"4125_CR11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/ibd\/izab163","volume":"28","author":"N Khan","year":"2022","unstructured":"Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Medvedeva E, Xie D, Yang YX. Efficacy of Vedolizumab in a nationwide cohort of elderly inflammatory bowel disease patients. Inflamm Bowel Dis. 2022;28:734\u201344.","journal-title":"Inflamm Bowel Dis"},{"key":"4125_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","volume":"16","author":"T Raine","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, Bachmann O, Bettenworth D, Chaparro M, Czuber-Dochan W, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16:2\u201317.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"4125_CR13","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","volume":"13","author":"A Sturm","year":"2019","unstructured":"Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 2: IBD scores and general principles and technical aspects. J Crohns Colitis. 2019;13(3):273\u201384.","journal-title":"J Crohns Colitis"},{"key":"4125_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New Engl J Med. 2013;369:699\u2013710.","journal-title":"New Engl J Med"},{"key":"4125_CR15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/apt.12616","volume":"39","author":"JP Gisbert","year":"2014","unstructured":"Gisbert JP, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. Aliment Pharm Ther. 2014;39:459\u201377.","journal-title":"Aliment Pharm Ther"},{"key":"4125_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/jcm13020365","volume":"13","author":"T Holvoet","year":"2024","unstructured":"Holvoet T, Truyens M, De Galan C, Peeters H, Gismero FM, Elorza A, Torres P, Vandermeulen L, Jauregui-Amezaga A, Ferreiro-Iglesias R, et al. Safety and Effectiveness of Vedolizumab and Ustekinumab in Elderly Patients with Inflammatory Bowel Disease: A Real-Life Multicentric Cohort Study. J Clin Med. 2024;13:365.","journal-title":"J Clin Med"},{"key":"4125_CR17","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/apt.15113","volume":"49","author":"MT Osterman","year":"2019","unstructured":"Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment Pharmacol Ther. 2019;49:408\u201318.","journal-title":"Aliment Pharmacol Ther"},{"key":"4125_CR18","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.3389\/fimmu.2017.01960","volume":"8","author":"T Fulop","year":"2018","unstructured":"Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and Inflamm-Aging as two sides of the same coin: friends or foes?? Front Immunol. 2018;8:1960.","journal-title":"Front Immunol"},{"issue":"8","key":"4125_CR19","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.3390\/nu13082764","volume":"13","author":"K Norman","year":"2021","unstructured":"Norman K, Ha\u00df U, Pirlich M. Malnutrition in older Adults-Recent advances and remaining challenges. Nutrients. 2021;13(8):2764.","journal-title":"Nutrients"},{"issue":"1","key":"4125_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/nu15010240","volume":"15","author":"A Sobolewska-W\u0142odarczyk","year":"2023","unstructured":"Sobolewska-W\u0142odarczyk A, Walecka-Kapica E, W\u0142odarczyk M, G\u0105siorowska A. Nutritional status indicators as a predictor of achieving remission at week 14 during Vedolizumab therapy in patients with ulcerative colitis: A pilot study. Nutrients. 2023;15(1):240.","journal-title":"Nutrients"},{"key":"4125_CR21","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/ecco-jcc\/jjab067","volume":"15","author":"B Ungar","year":"2021","unstructured":"Ungar B, Malickova K, Han\u017eel J, Abu Arisha M, Paul S, Rocha C, Ben Shatach Z, Abitbol CM, Haj Natour O, Selinger L, et al. Dose optimisation for loss of response to Vedolizumab- pharmacokinetics and immune mechanisms. J Crohns Colitis. 2021;15:1707\u201319.","journal-title":"J Crohns Colitis"},{"key":"4125_CR22","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1093\/ibd\/izy171","volume":"24","author":"E Shmidt","year":"2018","unstructured":"Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, et al. Predictors and management of loss of response to Vedolizumab in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:2461\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"4125_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","volume":"15","author":"BG Feagan","year":"2017","unstructured":"Feagan BG, Rubin DT, Danese S, Vermeire S, Abhyankar B, Sankoh S, James A, Smyth M. Efficacy of Vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol H. 2017;15:229\u201339.","journal-title":"Clin Gastroenterol H"},{"issue":"7","key":"4125_CR24","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3390\/jcm9072126","volume":"9","author":"P Scarozza","year":"2020","unstructured":"Scarozza P, De Cristofaro E, Scucchi L, Rocchetti I, Marafini I, Neri B, Salvatori S, Biancone L, Calabrese E, Monteleone G. Effect of Vedolizumab on Anemia of chronic disease in patients with inflammatory bowel diseases. J Clin Med. 2020;9(7):2126.","journal-title":"J Clin Med"},{"key":"4125_CR25","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.tips.2024.08.003","volume":"45","author":"P Wangchuk","year":"2024","unstructured":"Wangchuk P, Yeshi K, Loukas A. Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments. Trends Pharmacol Sci. 2024;45:892\u2013903.","journal-title":"Trends Pharmacol Sci"},{"key":"4125_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000527846","volume":"104","author":"T Sakurai","year":"2023","unstructured":"Sakurai T, Saruta M. Positioning and usefulness of biomarkers in inflammatory bowel disease. Digestion. 2023;104:30\u201341.","journal-title":"Digestion"},{"key":"4125_CR27","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/nu15153479","volume":"15","author":"M Godala","year":"2023","unstructured":"Godala M, Gaszynska E, Walczak K, Malecka-Wojciesko E. Evaluation of Albumin, Transferrin and Transthyretin in Inflammatory Bowel Disease Patients as Disease Activity and Nutritional Status Biomarkers. Nutrients. 2023;15:3479.","journal-title":"Nutrients"},{"key":"4125_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5217\/ir.2019.09159","volume":"19","author":"CJ Ooi","year":"2021","unstructured":"Ooi CJ, Hilmi IN, Kim HJ, Jalihal U, Wu DC, Demuth D, Lindner D, Adsul S. Efficacy and safety of Vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study. Intest Res. 2021;19:71\u201382.","journal-title":"Intest Res"},{"key":"4125_CR29","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jfma.2021.11.012","volume":"121","author":"CJ Kuo","year":"2022","unstructured":"Kuo CJ, Le PH, Tai WC, Wu KL, Yen HH, Yen CW, Tung SY, Chung CS, Su MY, Chiu CT. The effectiveness and safety of Vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study. J Formos Med Assoc. 2022;121:1689\u201395.","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"4125_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","volume":"76","author":"G Varkas","year":"2017","unstructured":"Varkas G, Thevissen K, De Brabanter G, Van Praet L, Czul-Gurdian F, Cypers H, De Kock J, Carron P, De Vos M, Hindryckx P, et al. An induction or flare of arthritis and\/or sacroiliitis by Vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 2017;76(5):878\u201381.","journal-title":"Ann Rheum Dis"},{"key":"4125_CR31","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1086\/313947","volume":"31","author":"SC Castle","year":"2000","unstructured":"Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis. 2000;31:578\u201385.","journal-title":"Clin Infect Dis"},{"key":"4125_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-physiol-021119-034610","volume":"82","author":"SJ Cho","year":"2020","unstructured":"Cho SJ, Stout-Delgado HW. Aging and lung disease. Annu Rev Physiol. 2020;82:433\u201359.","journal-title":"Annu Rev Physiol"},{"key":"4125_CR33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ibd\/zaa010.140","volume":"26","author":"N Khan","year":"2020","unstructured":"Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of infection and types of infection among elderly patients with inflammatory bowel disease: A retrospective database analysis. Inflamm Bowel Dis. 2020;26:462\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"4125_CR34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D\u2019Haens G, Panaccione R, Loftus EJ, Sankoh S, Fox I, et al. The safety of Vedolizumab for ulcerative colitis and crohn\u2019s disease. Gut. 2017;66:839\u201351.","journal-title":"Gut"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04125-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04125-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:09:36Z","timestamp":1757279376000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04125-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4125"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04125-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki (World Medical Association, 2024). The Ethics Committee of the Affiliated Hospital of Qingdao University authorised the study (Approval No. QYFY WZLL 28569). Additionally, the Ethics Committee of the Affiliated Hospital of Qingdao University waived the requirement for written informed consent due to this study\u2019s retrospective design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"531"}}